Neurizon Therapeutics Limited · ASX:NUZ
Neurizon Therapeutics — Pitt Street Research Life Sciences Conference 2019
15 slides from Neurizon Therapeutics's conference presentation, Nov 28, 2019
Slide 1: Pitt Street Research Life Sciences Conference
Pitt Street Research Life Sciences Conference 28 November 2019 ASX: PAA ACN 094 006 023 1
Slide 2: Corporate Structure
Corporate Structure 100% 100% Pitney Pharmaceuticals Limited Epichem Synthetic Medicinal Chemistry Pitney Pharmaceuticals: “repurposing” a Expected 2019-2020 sales A$ 4.2m+ registered drug (Monepantel) in oncology Pitt Street Research Life Sciences 28 November 2019 2
Slide 3: Corporate Snapshot
Corporate Snapshot ASX Code: PAA Total Shares on Issue 301,814,647 Market Cap at $0.11 $35M Options (Unlisted) 56,801,956 Cash (at 25 November 2019) $3.2M Debt (EFIC) $325K Top 20 Own 35% Epichem Revenue Forecast $4.2M Board/Exec Own 9.3% 2019-2020 Pitt Street Research Life Sciences 28 November 2019
Slide 4: Experienced Board & Management Team
Experienced Board & Management Team Dr. Roger Aston, Executive Chairman Sam Wright, Director & Company Secretary • > 30 years experience in the pharmaceutical and • > 20 years experience in biotech and healthcare. healthcare industries. • Extensive experience in relation to public company • Director
Slide 5: PharmAust Background
PharmAust Background • Lead product is Monepantel (MPL) – a repurposed drug already approved for Veterinary use by Elanco Animal Health (US $10.7b) • PharmAust patented MPL as an anti-cancer drug (mTOR pathway) • Clinical strategy targeting MPL for vet and human applications • Epichem: profitable bu
Slide 6: Elanco Animal Health – Option Agreement
Elanco Animal Health – Option Agreement • Elanco Animal Health (NYSE:ELAN) – MC=$10.7B US • Monepantel compound is owned by Elanco, approved for the treatment of parasitic infections in sheep (patent protection to 2024) • Option Agreement with Elanco to exclusive, worldwide royalty bearing license t
Slide 7: Product Areas of Focus
Product Areas of Focus ELANCO IS AN ESTABLISHED LEADER WITH FLAGSHIP BRANDS AND A GLOBAL PRESENCE. They’re focused on investing and innovating in the animal health priorities that mean the most to their customers and the animals in their care. COMPANION ANIMAL FOOD ANIMAL Pitt Street Research Life S
Slide 8: Monepantel (MPL) In Oncology
Monepantel (MPL) In Oncology A UNIQUE ANTI-CANCER PARADIGM • AVAILABILITY OF GMP • VERY LOW TOXICITY ON QUALITY DRUG MANUFACTURE ALLOWS HIGH NORMAL CELLS IN PLACE DOSE THERAPY • mTOR REGULATOR • ELANCO PROVIDES DRUG THROUGH PARTNER ACCESS TO VALIDATION IN • ALREADY REGISTERED AS A REGISTRATION VARIO
Slide 9: MPL And Chemotherapy (USD 52 billion)
Comparatives: MPL And Chemotherapy (USD 52 billion) THE SINGLE MOST IMPORTANT LIMITATION OF CHEMOTHERAPY IS DOSE LIMITING TOXICITY ACTIVITY MPL CHEMOTHERAPY PROGRESSION FREE SURVIVAL ++++ ++ IMMUNOSUPPRESSION + ++++ HIGH DOSE TOXICITY + +++++ RESISTANCE ? ++++ REGRESSION ++ +++++ Pitt Street Researc
Slide 10: >$2 Billion market for approved mTOR Drugs
>$2 Billion market for approved mTOR Drugs THE MORE IMPORTANT LIMITATIONS OF mTOR DRUGS ARE SIDE EFFECTS AND RESISTANCE https://www.novartis.com/investors/financial-data/product-sales; Rocco Monto, 2018 Pitt Street Research Life Sciences 28 November 2019 10
Slide 11: Initial Market - Pets and Cancer
Initial Market - Pets and Cancer • 6 million dogs diagnosed with cancer annually in the US • Significant unmet need for new oncology drugs (US$500m - USD$1b market = 25% of market) • Side effects associated with products and treatments are limiting market growth (Monepantel comparatively has minor s
Slide 12: Phase II Trial in Canines
Phase II Trial in Canines TARGETTING B CELL LYMPHOMA IN PET OWNERS’ DOGS • Despite poor taste and low dose, past trial in B cell lymphoma demonstrated successful outcome (14 days, 6/7 stable disease and reductions in tumour sizes) • Untreated, dogs get sicker and 50% mortality at 30 days (range: 1 –
Slide 13: PharmAust – Current Status and Next Steps
PharmAust – Current Status and Next Steps • Successful $2.0m Rights Issue to existing shareholders completed in April 2019 • Oversubscribed placement primarily to Australian and Singaporean fund management institutions raises $2.4m in October 2019 • Sufficient funds to complete Phase II in dogs as w
Slide 14: Pitt Street Research Life Sciences 28 November 2019
Pitt Street Research Life Sciences 28 November 2019 14
Slide 15: Disclaimer
Disclaimer This presentation has been prepared by PharmAust Limited (ASX: PAA) (ACN: 094 006 023) (the “Company”). It does not purport to contain all the information that a prospective investor may require in connection with any potential investment in the Company. You should not treat the contents
Neurizon Therapeutics — Pitt Street Research Life Sciences Conference 2019 on 6ix